SLV213 Treatment in COVID-19 Patients
SLV213 Treatment in COVID-19 Patients
This Phase 2a trial recruits adult ambulatory patients who have been determined to be
 COVID-19 positive. The study drug SLV213 will be administered to examine its safety,
 tolerability and provide assessment of its effect on clinical symptoms of COVID-19. Blood
 samples will be taken pre-dose and at several time points post-dose for pharmacokinetic (PK)
 analysis.
This double blind, placebo-controlled study will be conducted in two parts. Part A will
 determine the maximum tolerated dose (MTD) that will be used in Part B to confirm tolerance
 and provide assessment of the effect of SLV213 on clinical symptoms of COVID-19.

 Part A will consist of three sequential cohorts of 12 subjects receiving treatment
 administered orally either twice a day or once a day for seven consecutive days. Subjects in
 each cohort will be randomized to one of two treatment arms, SLV213 (8 subjects) or placebo
 (4 subjects). After each cohort, a Selva Safety Review Committee (SRC) will evaluate the
 safety of the regimen before proceeding to dose the next cohort. If a cohort is deemed to
 have reached an intolerable dose level, the dose prior to that level will be the MTD. PK
 blood samples will be collected throughout the study.

 In Part B of the study 45 subjects will be dosed at the MTD (30 SLV213 and 15 Placebo) to
 confirm tolerance, and to provide assessment of the effect of SLV213 on clinical symptoms of
 COVID-19. PK blood samples will be collected throughout the study.
Inclusion Criteria:

 1. Agree to participate in the trial by signing the IRB approved Informed Consent

 2. Age ≥ 18 years of age

 3. Positive diagnosis for COVID-19 by SARS-CoV-2 PCR by nasopharyngeal swab within the
 past 3 days

 4. Two or more COVID-19 symptoms (at least one of which must be Respiratory) rated Mild
 or Moderate on the COVID-19 adapted FLU-PRO Plus scale

 5. SpO2 ≥ 94 mm Hg

 6. Ambulatory (not hospitalized) at the time of enrollment

 7. At increased risk of developing more severe COVID-19 disease (at least one of the
 following):

 1. Age ≥60 years

 2. Presence of pulmonary disease, specifically moderate or severe persistent asthma,
 chronic obstructive pulmonary disease, pulmonary hypertension, emphysema

 3. Diabetes mellitus (type 1 or 2), requiring oral medication or insulin for
 treatment

 4. Cardiovascular disease, including Hypertension, requiring at least 1 oral
 medication for treatment; congestive heart failure; coronary artery disease;
 cardiomyopathy; pulmonary hypertension

 5. Body mass index ≥30

 6. Chronic renal disease (but not on dialysis)

 7. Sickle cell disease or trait

 8. Comorbid disease (as above) well controlled/stable in opinion of the Investigator

 9. Normal (or stable if abnormal per comorbidity) baseline ECG

 10. Men of child-bearing potential must use birth control with heterosexual partner(s)
 (abstinence or condoms)

 11. Women of child-bearing potential must meet all the following criteria:

 -  Use of birth control (abstinence, oral contraceptives, condoms, or intrauterine
 device)

 -  Test negative for β-subunit of HCG

 Exclusion Criteria:

 1. Pregnant or lactating

 2. Treatment with COVID-19 antiviral such as remdesivir or SARS-CoV-2 antibodies

 3. Prior COVID-19 vaccination or prior recovery from documented COVID-19 infection

 4. Severe or Critical COVID-19, as indicated by respiratory distress or shortness of
 breath at rest; Resp Rate ≥30/min; Heart rate ≥125/min; SpO2 ≤ 93% on room air or
 PaO2/FiO2 ≤ 300 if on supplemental O2

 5. Positive HIV or positive Hepatitis Panel

 6. Treatment with any medications known to be strongly metabolized by CYP3A4 or CYP2D6